COMPARE: Pharmacokinetic profiles of subcutaneous peginterferon beta-1a and subcutaneous interferon beta-1a over 2 weeks in healthy subjects
about
The innovative development in interferon beta treatments of relapsing-remitting multiple sclerosis.Elimination half-lives of interleukin-6 and cytokine-induced neutrophil chemoattractant-1 synthesized in response to inflammatory stimulation in rats.Interferons in Traumatic Brain and Spinal Cord Injury: Current Evidence for Translational Application.Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN
P2860
COMPARE: Pharmacokinetic profiles of subcutaneous peginterferon beta-1a and subcutaneous interferon beta-1a over 2 weeks in healthy subjects
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 April 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
COMPARE: Pharmacokinetic profi ...... er 2 weeks in healthy subjects
@en
COMPARE: Pharmacokinetic profi ...... r 2 weeks in healthy subjects.
@nl
type
label
COMPARE: Pharmacokinetic profi ...... er 2 weeks in healthy subjects
@en
COMPARE: Pharmacokinetic profi ...... r 2 weeks in healthy subjects.
@nl
prefLabel
COMPARE: Pharmacokinetic profi ...... er 2 weeks in healthy subjects
@en
COMPARE: Pharmacokinetic profi ...... r 2 weeks in healthy subjects.
@nl
P2093
P2860
P356
P1476
COMPARE: Pharmacokinetic profi ...... er 2 weeks in healthy subjects
@en
P2093
Ali Seddighzadeh
Bjørn Sperling
Brian Werneburg
Ivan Nestorov
Jawad Hasan
Katherine Dawson
Shulian Shang
P2860
P304
P356
10.1111/BCP.12968
P407
P577
2016-04-08T00:00:00Z